Photo of Steven O'Day from LinkedIn
Jun 13, 2024, 23:58
Steven O’Day shared the latest data and insights from our botensilimab programs – Agenus
Agenus shared on LinkedIn:
“Yesterday, our Chief Medical Officer, Dr. Steven O’Day, joined clinical experts and researchers at Nature Portfolio’s Cancer Immunotherapy conference in Boston, where he shared the latest data and insights from our botensilimab programs.
Thank you to all participants for the impactful discussion as we work together to advance the field of immunotherapy.”.
Source: Agenus/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46